Overview

Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macul

Status:
RECRUITING
Trial end date:
2030-02-01
Target enrollment:
Participant gender:
Summary
This will be a clinical study to assess initial safety and tolerability of IVT ABI-110 in patients diagnosed with wet macular degeneration (wAMD), including symptomatic macular PCV.
Phase:
PHASE1
Details
Lead Sponsor:
Avirmax Biopharma Inc